LEUKEMIA AND LYMPHOMA

Transcription

1 J O N AT H A N W O O D & A S S O C I A T E S An MDedge Company LEUKEMIA AND LYMPHOMA Europe and the US Linking Knowledge and Practice 3-5 October 2018 DUBROVNIK Valamar Lacroma Dubrovnik Hotel Dubrovnik, Croatia Co-chairs: Hagop Kantarjian, MD Professor and Chair Department of Leukemia Houston, TX, USA Srdan Verstovsek, MD, PhD Professor of Medicine Department of Leukemia Houston, TX, USA A collaboration by: The University of Texas The School of Medicine University of Zagreb Croatian Leukemia and Lymphoma Society Boris Labar, MD, PhD Associate Professor Department of Medicine Clinical Hospital Center Zagreb Zagreb, Croatia Exhibition and Sponsorship Prospectus Organized by:

2 Leukemia and Lymphoma 2018 organizer: Jonathan Wood & Associates, an MDedge Company 7 Century Drive Parsippany, NJ Phone: info@jwoodassoc.com

3 LEUKEMIA AND LYMPHOMA Europe and the US Linking Knowledge and Practice Valamar Lacroma Dubrovnik Hotel, Dubrovnik, Croatia 3-5 October, 2018 Dear Colleagues and Friends, It is our great pleasure to announce the multinational congress Leukemia & Lymphoma 2018 that will take place at the Valamar Lacroma Dubrovnik Hotel, Dubrovnik, Croatia, scheduled for 3-5 October We would like to invite you to be a part of this premier event! Leuk-Lymph.com This meeting is a joint effort of The University of Texas, Houston, Texas, USA; The School of Medicine, University of Zagreb, Zagreb, Croatia, organized by Jonathan Wood & Associates, an MDedge Company. The theme of the meeting, Europe and the US Linking Knowledge and Practice, reflects the collaboration to advance the research and treatment of patients with hematologic malignancies globally. Leukemia & Lymphoma 2018 will host nearly 500 delegates and approximately 50 renowned faculty from the US and Europe. The meeting will provide participants with a unique opportunity for sharing knowledge, skills, and experiences. In addition, this activity will provide a platform for networking with many of the world s leading experts, focusing on reviewing and assessing best practices and state of the art treatments across the spectrum of hematologic malignancies, including leukemias, lymphoma, myeloma, MDS, MPNs, and transplant. The meeting program will include presentations, round-table discussions, debates with audience participation, oral abstracts, poster sessions, and a number of informal social gatherings. As the Chairs of Leukemia & Lymphoma 2018, it is our pleasure to invite you to participate in this one-of-a-kind event. If you would like additional information or have any questions regarding the conference, please BD@jwoodassoc.com, or contact Damaris Cruz at or by , dcruz@jwoodassoc.com Hagop Kantarjian, MD Professor Of Medicine Department of Leukemia Houston, TX, USA Srdan Verstovsek, MD, PhD Professor of Medicine Department of Leukemia Houston, TX, USA Boris Labar, MD, PhD Associate Professor Department of Medicine Clinical Hospital Center Zagreb Zagreb, Croatia

4 CORPORATE SPONSORSHIP OPPORTUNITIES Leukemia & Lymphoma 2018 offers a forum for industry sponsors to participate in the exchange of information and ideas surrounding cutting edge developments in hematologic malignancies. The planning committee, faculty, and attendees alike appreciate the support of our industry partners. Without your contributions, educational events such as Leukemia & Lymphoma 2018 would not be possible. There are many opportunities for industry to sponsor the conference s educational programs, meeting materials, and services. Each opportunity promises to provide a significant presence for companies during the conference. Commensurate with the level of contribution, sponsors are acknowledged in all Leukemia & Lymphoma 2018 meeting materials and on the conference website. Corporate Sponsorship Opportunities

5 7:15 7:30 8:00 8:15 8:30 8:45 9:00 9:15 9:30 9:45 10:00 10:15 10:30 10:45 11:00 11:15 11:30 11:45 12:00 12:15 12:30 12:45 13:00 13:15 13:30 13:45 14:00 14:15 14:30 14:45 15:00 15:15 15:30 15:45 16:00 16:15 16:30 16:45 17:00 17:15 17:30 17:45 18:00 18:15 18:30 18:45 19:00 19:15 19:30 19:45 20:00 20:15 20:30 20:45 21:00 Wednesday, October 03 Thursday, October 04 Friday, October 05 Registration Keynote Address Acute Lymphocytic Leukemias Acute Myeloid Leukemias Welcome Dinner Morning Symposium Myeloproliferative Neoplasms Myelodysplactic Syndromes Lunch Symposium Chronic Myeloid Leukemias Chronic Lymphocytic Leukemias Oral Poster Presentations Poster Walk Reception Morning Symposium B-Cell Lymphomas T-Cell Lymphomas Lunch Symposium Multiple Myeloma Program At A Glance

6 Program Agenda AGENDA DAY 1 Wednesday, October 3, :00-14:10 Welcome and Introduction of Keynote Presenter Boris Labar (Croatia) 14:10-15:00 Keynote Address: State of the Art Therapy for CML Hagop Kantarjian (USA) SESSION 1: ACUTE LYMPHOCYTIC LEUKEMIAS Moderators: Boris Labar, Farhad Ravandi 15:05-15:20 Prognostic implications of cytogenetic aberrations and molecular mutations in acute leukemia Claudia Haferlack (Germany) 15:25-15:40 Significance of minimal residual disease in the acute leukemias Monika Bruggemann (Germany) 15:45-16:00 Impact of TKIs on Philadelphia chromosome+ ALL Elias Jabbour (USA) 16:05-16:20 Therapeutic options for Philadelphia chromosome-like ALL Sabina Chiaretti (Italy) 16:25-16:40 Treatment of Adolescents and Young Adults with ALL Jean-Pierre Marie (France) 16:45-17:00 How should we treat older patients with ALL? Max Topp (Germany) 17:05-17:20 BREAK SESSION 2: ACUTE MYELOID LEUKEMIAS Moderators: Boris Labar, Farhad Ravandi 17:20-17:35 Targeted therapy for AML using FLT3 and IDH1/2 inhibitors Stephane de Botton (France) 17:40-17:55 Monoclonal antibodies and checkpoint inhibitors in AML Farhad Ravandi (USA) 18:00-18:15 CPX351 and other novel therapies for AML Jeffrey Lancet (USA) 18:20-18:35 CAR T cell therapy for acute leukemia Stephen Grupp (USA) 18:40-19:00 How will solving GVHD impact transplantation for acute leukemias? Nikolas von Bubnoff (Germany) 19:00 Welcome Dinner/Reception DAY 2 Thursday, October 4, :30-9:00 Morning Symposium SESSION 3: MYELOPROLIFERATIVE NEOPLASMS Moderators: Pierre Fenaux, Srdan Verstovsek 9:05-9:20 Polycythemia Vera: Diagnosis and management Alessandro Vannucchi (Italy) 9:25-9:40 Primer on atypical myeloproliferative neoplasms Andreas Reiter (Germany) 9:45-10:00 What exactly is myelomonocytic leukemia? Differentiating CMML from everything else Nadira Durakovic (Croatia) 10:05-10:20 JAK inhibitors for all classical Philadelphia negative MPN Srdan Verstovsek (USA) 10:25-10:40 The MPN QOL International Study Group: Is quality of life a legitimate therapeutic target? Claire Harrison (UK) 10:45-11:00 Stem cell transplantation for Philadelphia chromosome-negative MPNs in 2018 Jane Apperley (UK) 11:05-11:20 BREAK SESSION 4: MYELODYSPLASTIC SYNDROMES Moderators: Pierre Fenaux, Srdan Verstovsek 11:20-11:35 ICUS/CHIP/CCUS: What determines a correct diagnosis? Ghulam Mufti (UK) 11:40-11:55 Molecular determinants of MDS Luca Malcovati (Italy) 12:00-12:15 Frontline therapy of low-risk MDS Valeria Santini (Italy) 12:20-12:35 Frontline therapy of high-risk MDS Uwe Platzbecker (Germany) 12:40-12:55 What novel new therapies may mean for the future of MDS Pierre Fenaux (France) 13:00-13:20 When should transplant be offered as an option for MDS Mateo Della Porta (Italy) 13:20-15:00 Lunch Symposium

7 SESSION 5: CHRONIC MYELOID LEUKEMIAS Moderators: Michael Hallek, Hagop Kantarjian 15:00-15:15 Is minimal residual disease as significant in chronic leukemias as it is in acute leukemias? William Wierda (USA) 15:20-15:35 Modulating the efficacy of tyrosine kinase inhibitors in CML Jorge Cortes (USA) 15:40-15:55 What have we learned from the CML European Treatment and Outcomes Study? Michele Baccarani (Italy) 16:00-16:15 How quality of life issues impact choice of therapy for CML: GIMEMA and EORTC Quality of Life Group Fabio Efficace (Italy) 16:20-16:35 BREAK SESSION 6: CHRONIC LYMPHOCYTIC LEUKEMIAS Moderators: Michael Hallek, Hagop Kantarjian 16:35-16:50 Molecular signature of CLL Davide Rossi (Italy) 16:55-17:10 Frontline therapy in CLL Michael Hallek (Germany) 17:15-17:30 Therapy of older patients with CLL Emili Montserrat (Spain) 17:35-17:50 Novel agents in CLL Susan O Brien (USA) 17:55-18:15 Transplantation for CLL Peter Dreger (Germany) SESSION 7: ORAL POSTER PRESENTATIONS 18:15-19:00 TBA 19:00-20:00 Poster walk reception DAY 3 Friday,October 5, :30-9:00 Morning Symposium SESSION 7: B-CELL LYMPHOMAS Moderators: Tim Illidge, Nathan Fowler 9:05-9:20 Overcoming anti-cd20 refractory disease in BCL with newer antibodies Guillaume Cartron (France) 9:25-9:40 Managing relapsed/refractory Hodgkin lymphoma Tim Illidge (UK) 9:45-10:00 Targeting the microenvironment in B-cell lymphoma Nathan Fowler (USA) 10:05-10:20 Next generation approaches in primary CNS lymphoma Gerald Illerhaus (Germany) 10:25-10:40 Looking beyond R-CHOP in diffuse large B-cell lymphoma Marek Trneny (Czech Republic) 10:45-11:00 Moving beyond CHOP in mantle cell lymphoma Simon Rule (UK) 11:25-11:40 BREAK SESSION 8: T-CELL LYMPHOMAS Moderators: Madeleine Duvic, Ali Bazarbachi 11:45-12:00 Integrating immunotherapy into treatment paradigms for CTCL Madeleine Duvic (USA) 12:05-12:20 Targeting the T-cell receptor pathway in peripheral T-cell lymphoma Pier Luigi Zinzani (Italy) 12:25-12:40 Enhancing targeted therapies with epigenetic agents in PTCL Owen O Connor (USA) 12:45-13:05 Is there a role for ASCT in adult T-cell lymphoma? Ali Bazarbachi (Lebanon) 13:05-14:35 Lunch Symposium SESSION 9: MULTIPLE MYELOMA Moderators: Nikhil Munshi, Pieter Sonneveld 14:35-14:50 Prognostic factors in multiple myeloma Jesus San Miguel (Spain) 14:55-15:10 Managing asymptomatic multiple myeloma Dirk Hose (Germany) 15:15-15:30 Immunotherapy for multiple myeloma: update on the IMIDS Nikhil Munshi (USA) 15:35-15:50 Maintenance therapy in multiple myeloma Pieter Sonneveld (The Netherlands) 15:55-16:10 Minimal residual disease in multiple myeloma Herve Avet-Loiseau (France) 16:15-16:35 New antibodies for multiple myeloma Antonio Palumbo (Italy) 16:35 Closing remarks Program Agenda

8 LEUK-LYMPH.COM